Management and prevention of hereditary angioedema attacks

American Journal of Managed Care

Volumn 19, Issue 7 SUPPL, 2013, Pages

  Lumry, William R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; BRADYKININ; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ICATIBANT; ORAL CONTRACEPTIVE AGENT; PLACEBO; TRANEXAMIC ACID; PEPTIDE; DRUG DERIVATIVE;

ANGIONEUROTIC EDEMA; BLINDNESS; DENTAL PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SELF ADMINISTRATION; EMOTIONAL STRESS; ENDOTRACHEAL INTUBATION; HEALTH SERVICE; HOME CARE; HORMONE SUBSTITUTION; HUMAN; LACTATION; LARYNX EDEMA; LONG TERM CARE; MOUTH HYGIENE; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SHORT COURSE THERAPY; TRACHEOTOMY; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY; CHILD; CLINICAL TRIAL (TOPIC); COST OF ILLNESS; FEMALE; MALE; PATHOPHYSIOLOGY; PREGNANCY; PROCEDURES; SECONDARY PREVENTION; UNITED STATES; YOUNG ADULT; ARTICLE; METHODOLOGY;

ADOLESCENT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; CHILD; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; FEMALE; HUMANS; MALE; PEPTIDES; PREGNANCY; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84899467475     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359:1027-1036.
2. Morgan BP. Hereditary angiogedema - therapies old and new. N Engl J Med. 2010;363:581-583.
3. Bork K, Barnstedt S-E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Int Med. 2001;161:714-718. (Pubitemid 32200225)
4. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67:147-157.
5. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109:395-402.
6. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López- Trascasa M. Hereditary angiogedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498-503. (Pubitemid 40547939)
7. Agostoni A, Aygören-Pürsün E, Brinkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131. (Pubitemid 39200689)
8. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol. 2011;106:316-322.
9. Kalfus IN, Gower RG, Riedl M, Bernstein JA, Lumry WR, Frank MM. Hereditary angiogedema: implications of treating a rare disease. Ann Allergy Asthma Immunol. 2012;109:150-151.
10. FDA approves Berinert to treat abdominal attacks, facial swelling associated with hereditary angioedema. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm186257.htm. Accessed December 16, 2012.
11. Berinert [prescribing information]. Kankakee, IL: CSL Behring GmbH; 2012.
12. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801-808.
13. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks - final results of the IMPACT2 study. Allergy. 2011;68:1604-1611.
14. CSL Behring press release; January 3, 2012. CSL Behring receives FDA approval of expanded label on Berinert for selfadministration and treatment of acute laryngeal attacks of hereditary angioedema. http://www.cslbehring.com/s1/ cs/enco/1151517263302/news/1255927937141/prdetail.htm. Accessed December 31, 2012.
15. Summary Basis for Regulatory Action - CINRYZE. US Food and Drug Administration website. http://www.fda.gov/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/ucm093617.htm. Accessed May 10, 2013.
16. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513-522.
17. Zuraw BL. The pathophysiology of hereditary angioedema. World Allergy Organ J. 2010;3:S25-S28.
18. Davies A III. The pathogenesis of hereditary angioedema. Transfus Apher Sci. 2003;29:195-203.
19. Kalbitor [prescribing information]. Cambridge MA: Dyax Corp; 2012.
20. US Food and Drug Administration (FDA). FDA approves Kalbitor for treating potentially life-threatening attacks of hereditary angioedema. FDA website. Accessed December 17, 2012. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm192687.htm.
21. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523-531.
22. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523-529.
23. Scheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of two double-blind, phase 3 studies. J Allergy Clin Immunol. 2011;128:153-159.
24. Firazyr [prescribing information]. Lexington MA: Shire Orphan Therapies, Inc; 2011.
25. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin- receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532-541.
26. Lumry WR, Li HH, Levy RJ, et al. Randomized, placebo controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529-537.
27. Moellman JJ, Bernstein JA. Diagnosis and management of hereditary angioedema: an emergency medicine perspective. J Emerg Med. 2012;43:391-400.
28. Cohen N, Sharon A, Golik A, Zaidenstein R, Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. J Clin Gastroenterol. 1993;16(3):237-239. (Pubitemid 23106894)
29. Bowen T, Cicardi M, Farkas H, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clinl Immunol. 2010;6:24.
30. Cinryze [prescribing information]. Exton, PA: ViroPharma Biologics, Inc; 2012.
31. Bernstein J, Manning M, Li H, et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Oral Abstract Presentation #34 presented at ACAAI Annual Meeting, Anaheim, CA, November 2012.
32. Danazol [prescribing information]. Sellersville, PA: TEVA Pharmaceuticals USA; 2012.
33. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100:153-161. (Pubitemid 351238551)
34. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308-320.
35. Craig T, Pürsün EA, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5:182-199.
36. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6:18.
37. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Clinical trial experience of pediatric patients treated with ecallantide for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2012;109(5 suppl):A123-A124. Abstract P303.
38. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22.